Cas:115605-28-2 (4-methyl-1,3-benzothiazol-2-yl)urea manufacturer & supplier

Chemical Name:(4-methyl-1,3-benzothiazol-2-yl)urea

CAS.NO:115605-28-2

Synonyms:(4-methyl-1,3-benzothiazol-2-yl)urea

Molecular Formula:C₉H₉N₃OS

Molecular Weight:207.25200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:97.24000

Exact Mass:207.04700

LogP:2.68210

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (4-methyl-1,3-benzothiazol-2-yl)urea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-methyl-1,3-benzothiazol-2-yl)urea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-methyl-1,3-benzothiazol-2-yl)urea Use and application,(4-methyl-1,3-benzothiazol-2-yl)urea technical grade,usp/ep/jp grade.

Related News: Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. (4-methyl-1,3-benzothiazol-2-yl)urea manufacturer China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. (4-methyl-1,3-benzothiazol-2-yl)urea supplier China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. (4-methyl-1,3-benzothiazol-2-yl)urea vendor Alira is one of many in the CRO space to ink deals in recent months. Altasciences acquired preclinical CRO Calvert Laboratories in May, weeks after itself being bought out by Novo Holdings, and a few months after buying early-stage CRO WCCT Global. (4-methyl-1,3-benzothiazol-2-yl)urea factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.